BIO 2016 session preview: “No Patent, No Cure”

Effective patent protection is one of the key drivers of the research-intensive high-tech biotechnology sector (including start-ups and small and medium-sized enterprises), which stands out as one of the global industries with the highest percentage of sales re-invested in research and development.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

CRISPR patents revoked following Nobel Prize winners’ withdrawal

White & Case hires experienced litigator from A&O Shearman

China’s new policies on foreign investment in healthcare and biotech

BIO 2016 session preview: “No Patent, No Cure”

Editor's picks

Editor's picks

More features